Ketamine for Continuous Infusion as Analgesic
For adult patients requiring continuous ketamine infusion for analgesia, initiate with a loading dose of 0.5 mg/kg IV after anesthesia induction, followed by a continuous infusion of 0.125-0.25 mg/kg/h (maximum 0.5 mg/kg/h), primarily reserved for high-risk pain scenarios or opioid-dependent patients. 1
Primary Indications
Ketamine continuous infusion is not recommended for routine analgesic use but should be specifically targeted to:
- Surgery with high risk of acute or chronic postoperative pain (major abdominal, pelvic, or spinal procedures)
- Patients with vulnerability to pain, particularly those on long-term opioids or with opioid addiction
- Opioid-refractory pain in critically ill mechanically ventilated patients 1, 2
The 2019 expert panel guidelines emphasize this selective approach with strong agreement (G1+), noting that ketamine functions primarily as an anti-hyperalgesic adjunct rather than a standalone analgesic 1.
Dosing Protocol
Intraoperative/Perioperative Use
Loading dose: 0.5 mg/kg IV administered after anesthesia induction (not before) to prevent psychodysleptic side effects 1
Continuous infusion: 0.125-0.25 mg/kg/h
- Maximum rate: 0.5 mg/kg/h (FDA label specifies 0.1-0.5 mg/min for maintenance anesthesia) 1, 3
- For S-ketamine: reduce dose by 50% (0.25-0.5 mg/kg loading, same infusion rates) 4
Critical timing consideration: Stop infusion 30 minutes before end of surgery 1. This is essential because continuation into the postoperative period increases hallucination risk without significantly enhancing analgesia.
ICU/Critical Care Use
For mechanically ventilated adults with opioid-refractory pain:
Loading dose: 0.5 mg/kg IV push Continuous infusion: 1-2 μg/kg/min (equivalent to 0.06-0.12 mg/kg/h) 2
A 2018 critical care guideline provides conditional recommendation (very low quality evidence) for this approach, noting it reduces morphine consumption by approximately 22 mg over 24 hours 2.
Duration and Titration
Intraoperative duration: Continue until 30 minutes before surgical completion 1
Postoperative continuation is NOT recommended due to:
- Increased hallucination risk
- Minimal additional analgesic benefit
- Uncertain impact on chronic pain prevention beyond 24 hours 1
ICU duration: Median 33-75 hours in published cohorts, though optimal duration remains undefined 5, 6, 7. One study documented safe use up to 493 hours 8.
Titration approach: When used for chronic pain management, gradual dose escalation prevents psychotomimetic effects:
- Start: 10 mg/day continuous IV
- Increase by 10 mg/day every 4-6 hours until 50 mg/day
- Then increase by 25 mg/day every 12-24 hours as needed
- Psychotomimetic effects rare below 300 mg/day with this approach 9
Monitoring Requirements
Mandatory monitoring per FDA label 3:
- Continuous vital signs monitoring
- Immediate availability of emergency airway equipment
- Administration only by physicians experienced in airway management
- Administer antisialagogue prior to induction (due to salivation risk)
Specific parameters to track:
- Heart rate (may decrease from baseline, contrary to traditional teaching) 5
- Blood pressure (generally stable; no significant vasopressor requirement changes) 5
- Respiratory rate (typically decreases slightly) 5
- Sedation level (RASS scores improve with ketamine) 7
Common adverse effects (24% incidence in multicenter cohort):
- Tachycardia (6%)
- Sialorrhea (6%)
- Hallucinations (increased with postoperative continuation)
- Emergence delirium (mitigated by benzodiazepines) 1, 6
Critical Caveats and Pitfalls
Do NOT administer 100 mg/mL concentration IV without dilution 3. Dilute with equal volume of sterile water, normal saline, or D5W. Use immediately after dilution.
Avoid in patients who have not followed NPO guidelines due to aspiration risk despite preserved airway reflexes 3.
Genitourinary toxicity: With chronic off-label use, monitor for genitourinary pain and consider cessation if symptoms develop 3.
Benzodiazepine co-administration: Strongly recommended to prevent emergence phenomena and neuropsychological manifestations 1, 3.
Expected Outcomes
Analgesic efficacy:
- Reduces acute pain intensity for 24 hours (moderate evidence)
- Decreases morphine consumption by mean 15 mg/24 hours
- Reduces postoperative nausea/vomiting risk
- May decrease chronic pain incidence by 30% at 3 months (low evidence) 1
Opioid-sparing effect in ICU:
- 20% median reduction in total analgesic-sedative requirements at 24 hours
- Fentanyl doses decreased from median 175 μg/h to 125 μg/h
- Propofol doses decreased from median 42.5 μg/kg/min to 20 μg/kg/min 7
Sedation quality: Time within goal RASS improved from 7.1% to 25% after ketamine initiation 7.
Contraindications to Continuous Infusion
While the FDA label lists relative contraindications for anesthetic doses, for analgesic continuous infusion specifically avoid in:
- Conditions where blood pressure elevation is hazardous (though hemodynamic stability generally maintained at analgesic doses)
- Active psychosis (relative contraindication)
- Patients unable to be monitored continuously
The evidence base for ketamine as continuous analgesic infusion remains limited, with most high-quality guidelines focusing on perioperative bolus dosing rather than prolonged infusions. The 2019 French expert panel provides the strongest guidance (G1+ recommendation) but explicitly recommends against postoperative continuation 1. ICU use has conditional support but relies on very low-quality evidence 2.